Periodic Reporting for period 1 - GRIPonMASH (GRIP on MASH: Global Research Initiative for Patient Screening on MASH)
Reporting period: 2023-12-01 to 2024-11-30
GRIPonMASH will address the unmet public health need of reducing disease burden and comorbidities associated with Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD).
Our goal is to increase the number of people diagnosed, create awareness about the lifestyle changes needed to address the disease, and to decrease the number of people with MASH and liver cancer. We aim to do this by designing and optimizing a sustainable and scalable GRIPonMASH diagnostic platform.
The platform will provide:
Screening, diagnosis, management and long-term follow-up of MASH high-risk patients to ensure early detection
Development of decision support tools and testing of existing and novel biomarkers for the detection of MASH patients through artificial intelligence-based decision support tools
Development of non-invasive alternatives to diagnostic liver biopsies
Assessment and personalization of lifestyle advice based on factors like physical activity, diet, sleep, smoking, alcohol consumption, and perception of stress.
By early detection and diagnosis of MASH we can improve the lives of patients and help healthcare professionals to focus on early treatment through proven lifestyle interventions.
Our goal is to increase the number of people diagnosed, create awareness about the lifestyle changes needed to address the disease, and to decrease the number of people with MASH and liver cancer. We aim to do this by designing and optimizing a sustainable and scalable GRIPonMASH diagnostic platform.
The platform will provide:
Screening, diagnosis, management and long-term follow-up of MASH high-risk patients to ensure early detection
Development of decision support tools and testing of existing and novel biomarkers for the detection of MASH patients through artificial intelligence-based decision support tools
Development of non-invasive alternatives to diagnostic liver biopsies
Assessment and personalization of lifestyle advice based on factors like physical activity, diet, sleep, smoking, alcohol consumption, and perception of stress.
By early detection and diagnosis of MASH we can improve the lives of patients and help healthcare professionals to focus on early treatment through proven lifestyle interventions.
The main achievements in the first year of the project include:
1.First patient successfully screened
A significant milestone achieved during the first year was the inclusion of the first patient in the study in Rotterdam. Other sites followed shortly in including patients for the screening in the study. This will allow the consortium to set up a biobank and data science platform to test both existing and novel biomarkers, and to leverage artificial intelligence-based technology to improve the detection of MASH. In the coming year all 12 hospitals/research institutes in the consortium will start screening patients to reach the target of 10.000 patients screened as stated in the agreement.
2. Pilot diagnostic platform
The first year also saw the development of the GRIPonMASH diagnostic platform by ways of a pilot study conducted at Amsterdam UMC. When tested sufficiently, the platform will be rolled out across all 12 participating clinical sites.
3. Lifestyle assessment
Another key milestone was developing and selecting questionnaires to explore lifestyle habits linked to metabolic dysfunction-associated steatotic liver disease (MASLD). The healthcare professionals at the 12 GRIPonMASH locaions also received training in accurately capturing dietary information. The findings will provide valuable guidance for healthcare professionals, researchers, and patients in developing personalized lifestyle approaches.
1.First patient successfully screened
A significant milestone achieved during the first year was the inclusion of the first patient in the study in Rotterdam. Other sites followed shortly in including patients for the screening in the study. This will allow the consortium to set up a biobank and data science platform to test both existing and novel biomarkers, and to leverage artificial intelligence-based technology to improve the detection of MASH. In the coming year all 12 hospitals/research institutes in the consortium will start screening patients to reach the target of 10.000 patients screened as stated in the agreement.
2. Pilot diagnostic platform
The first year also saw the development of the GRIPonMASH diagnostic platform by ways of a pilot study conducted at Amsterdam UMC. When tested sufficiently, the platform will be rolled out across all 12 participating clinical sites.
3. Lifestyle assessment
Another key milestone was developing and selecting questionnaires to explore lifestyle habits linked to metabolic dysfunction-associated steatotic liver disease (MASLD). The healthcare professionals at the 12 GRIPonMASH locaions also received training in accurately capturing dietary information. The findings will provide valuable guidance for healthcare professionals, researchers, and patients in developing personalized lifestyle approaches.
Not applicable for this reporting period.